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Globally, the hepatitis C virus (HCV) is an infection of increasing 
significance.[1] First clinically described as a cause of ‘non-A, non-B’ 
post-transfusion hepatitis, it was cloned, named, and characterised 
in 1989.[2] An estimated 170 million people are chronically infected 
with HCV, predominantly in Africa, Asia, Eastern Europe and South 
America.[3]
HCV is a positive-sense RNA virus of the Flaviviridae family, 
residing in cell cytoplasm.[2] It infects mostly hepatocytes and can be 
cleared spontaneously by effective host immune responses in 18 - 34% 
of cases.[2] The remainder progress to chronic infection, as the virus 
evades clearance owing to a variety of immune escape mechanisms. 
Re-infection can occur spontaneously or after treatment-associated 
viral clearance.[1,2] 
Clinical presentation and diagnosis
Clinically, HCV is initially asymptomatic.[2] In 20 - 40% of cases, 
chronic infection leads to fibrosis, cirrhosis and end-stage liver 
failure over 20 - 30 years.[2] Established cirrhosis has a 1 - 5% annual 
risk of hepatocellular carcinoma (HCC) and a 3 - 6% risk of hepatic 
decompensation.[2] Following hepatic decompensation, the risk of 
death over the ensuing year is 15 - 20%.[2] Accelerated progression 
is associated with co-infection with hepatitis B virus (HBV) and/or 
HIV, alcohol use, obesity and iron-overload state.[2,4,5]
Serological tests confirm HCV exposure and are useful for 
screening. First-generation HCV IgG ELISA tests were nonspecific, 
and most current peer-reviewed publications exclude these studies. 
Second-, third- and fourth-generation serological tests are acceptable, 
although there are notable accuracy issues in HIV co-infection and 
among black Africans.[6-8]
Region-specific HCV screening algorithms have been developed to 
try to reliably exclude false positives (≤25%) and to identify resolved, 
possible acute or possible chronic infection to guide subsequent 
management.[7-9]
The reverse transcriptase polymerase chain reaction (RT-PCR) is 
the gold standard test for HCV, signifying active infection, and allows 
for qualitative or quantitative testing.[2] Further nucleic acid tests 
confirm genotype.
Acute HCV infection in HIV-positive patients leads to a long, 
possibly irregular latency period before seroconversion. Therefore, 
Kaplan-Lewis and Fierer[10] argue for regular liver function test 
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Background. Hepatitis C virus (HCV) is a chronic infection of increasing importance, especially among people living with HIV/AIDS. 
Co-infection with HIV can accelerate progression of HCV liver disease to cirrhosis and end-stage liver failure and elevate the risk of 
hepatocellular carcinoma. Globally, men who have sex with men (MSM) and people who inject drugs are at increased risk of HCV infection 
compared with the general population. Few studies on HCV in these key populations have been done in South Africa (SA). 
Objective. To describe the disease burden of HCV in drug-using MSM who attend harm-reduction services at the Anova Health Institute’s 
Health4Men clinic in Cape Town, SA.
Methods. In 2012 - 2014, attendees of an MSM-focused harm-reduction programme were invited to participate in our study. After informed 
consent, participants completed a brief demographic questionnaire and underwent phlebotomy for anti-HCV antibody, hepatitis B virus 
(HBV) surface antigen and surface antibody testing. Participants received counselling and education with regard to their results. HIV 
status was extracted from the case notes of participants who had previously been tested at the study site. Data were analysed using standard 
statistical techniques. 
Results. Forty-one MSM were enrolled – 11 (27.0%) tested anti-HCV antibody-positive, indicating prior exposure to HCV or chronic 
infection; 10/11 (91.0%) were positive for HBV surface antibodies, suggesting previous HBV exposure or vaccination; and 1 (2.0%) screened 
positive for HBV. Of the HCV-seropositive individuals, HIV status was known in 8/11; 3/8 (37.5%) were HIV-positive. 
Conclusion. We demonstrated a high burden of HCV exposure or infection among a small urban cohort of MSM who inject drugs. We 
recommend active screening of MSM (especially those who report drug use) for HCV, and the development of referral networks for access 
to treatment. 
S Afr Med J 2017;107(12):1116-1120. DOI:10.7196/SAMJ.2017.v107i12.12623
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screening as a more sensitive indicator of incident infection in HIV-
positive patients.
HCV infection is curable and the new oral regimens with direct-
acting antiviral (DAA) agents have revolutionised management. 
Successful treatment halts or slows the progression to chronicity, 
fibrosis, cirrhosis, end-stage renal failure and HCC.[2,5] 
HCV and HIV
HIV and HCV co-infection occurs, in part due to shared transmission 
routes and behavioural risk factors.[2,4]
Evidence for HCV changing the course of HIV disease is 
equivocal,[4,10] but a considerable body of evidence shows that HIV 
changes the course of HCV progression. HIV-positive patients have 
higher HCV viral loads with lower clearance rates,[2,4] seroconversion 
(becoming HCV IgG-seropositive) occurs later or might not occur,[8] 
the progression to liver fibrosis, cirrhosis and end-stage liver disease 
is faster, and HCC incidence rates are higher.[2,4,5]
Some HIV-positive patients demonstrate ultra-rapid progression 
of hepatic fibrosis to cirrhosis and end-stage liver disease within 3 - 8 years 
of acute HCV infection.[10] The rapid progression seems to be related 
to acute HCV with significant immune suppression, but can occur at 
higher CD4+ counts.[4]
Transmission and epidemiology 
Before 1992, blood transfusion was an important risk factor for HCV 
infection. Nosocomial infection is a problem for patients receiving 
haemodialysis.[11] Unsafe injecting practices, tattooing, scarification, 
and medical parenteral drug administration are additional risk 
factors.[2,4] The predominant route of transmission is unknown in 
parts of central Africa, e.g. Cameroon, where HCV is endemic, with 
rates of ≥6% in the general population.[6]
The injection of drugs is currently one of the most important routes 
of transmission owing to unsafe injecting practices, such as sharing of 
needles, syringes and drug-use paraphernalia. HCV seroprevalence 
rates among people who inject drugs (PWID) can be ≤90%.[4]
There is not much evidence for the sexual transmission of 
HCV during monogamous heterosexual sex.[5] Sexually transmitted 
infections (STIs), HIV and multiple sexual partners increase the risk 
of HCV infection.[12] The sexual behaviour of men who have sex with 
men (MSM) is an important risk factor for transmission of HIV and 
HCV.[12]
Epidemics of HCV in HIV-positive MSM have been documented 
since the 1990s in Europe, North America, Asia, and Australia.[1,13] 
There are also reports of high rates of HCV in HIV-positive MSM in 
KwaZulu-Natal and Cape Town, South Africa (SA).[14,15] 
People living with HIV/AIDS (PLWHA) have higher odds of 
being HCV-seropositive than those without HIV, with a pooled 
odds ratio (OR) of 5.8 (95% confidence interval (CI) 4.5 - 7.4) in a 
recent (2016) World Health Organization (WHO)-commissioned 
global HIV/HCV co-infection review and meta-analysis authored 
by Platt et al.[16] In the review, median co-infection prevalence rates 
(HIV/HCV) differed by population, being 2.4% (interquartile range 
(IQR) 0.8 - 5.8) for general populations, 6.4% (IQR 3.2 - 10.0) for 
MSM and 82.4% (IQR 55.2 - 88.5) among PWID.
Africa and South Africa
In Africa, HCV seroprevalence varies regionally. In Egypt, adult 
seroprevalence among the general population is very high (14.70%; 
95% CI 10.30 - 18.00). There are high rates in central Africa (6.76%; 
95% CI 5.98 - 7.55), and lower rates in west Africa (4.34%; 
95% CI 3.99 - 4.70), with the lowest rates in east and southern 
Africa (0.91%; 95% CI 0.80 - 1.20).[6]
SA is thought to have low rates of HCV in the general population, 
but with regional and population differences. Table 1 summarises 
reported HCV seroprevalence rates among differing cohorts. These 
generally confirm a low seroprevalence in many provinces – Gauteng, 
Limpopo, and the Western Cape, with the notable exception of 
KwaZulu-Natal.
Few studies have been conducted among MSM PWID in SA. Our 
study is an exploratory project to enlarge the information base about 
MSM who use drugs and to highlight the need for further research.
Study design
The Ivan Toms Centre for Men’s Health (ITCMH) is operated by 
the Anova Health Institute with funding from the US President’s 
Emergency Plan for AIDS Relief/US Agency for International 
Development (PEPFAR/USAID) Global Fund and the Elton John 
AIDS Foundation, in collaboration with the National Department 
of Health. The ITCMH offers MSM primary healthcare services 
related to sexual health, including STI diagnosis and treatment, 
HIV testing, antiretroviral treatment, post-exposure prophylaxis 
(PEP) and pre-exposure prophylaxis (PrEP). The ITCMH has been 
providing services to key populations since 2010 and has extensive 
experience in working with them. In 2012, an MSM-targeted 
drug harm-reduction programme, including needle exchange, but 
lacking opioid-substitution therapy, was established, funded by the 
AIDS Fonds, Mainline, the Netherlands. This service, the first of 
its kind in SA, was delivered at the ITCMH, which is a centre of 
excellence and forms part of Anova’s Health4Men Initiative. The 
harm-reduction programme was in operation for about 18 months, 
when it was halted owing to a lack of sustainable funding. All 
programmatic knowledge and materials were subsequently handed 
over to the TB HIV Care Association, which received funding to 
continue services based on the Anova model. 
Harm-reduction programme attendees were approached and 
screened for enrolment in this study. Inclusion criteria included: 
adult male, reporting MSM, existing client of the harm-reduction 
programme, not known to be HCV-positive, able to understand 
study procedures, and provision of informed consent. Exclusion 
criteria included: women, age <18 years, exclusive heterosexuality, 
intoxication during clinic visit, and unable or unwilling to give 
informed consent. People who met the inclusion criteria provided 
written informed consent to participate. Research activities were 
approved and overseen by the Human Sciences Ethics Committee, 
University of Cape Town. 
Respondents who consented completed a short researcher-
administered questionnaire, including questions about 
participants’ demographics, health (e.g. prior STIs, viral hepatitis 
screening, vaccination and treatment, HIV and health access), 
sexual behaviour and drug use behaviour. Venous blood was 
drawn for HCV IgG (and HBV surface antigen and antibody) tests. 
Participants were requested to return for their results 2 weeks after 
study enrolment. They were provided counselling regarding their 
results and were linked to care if they screened positive for viral 
hepatitis. HBV-susceptible participants were vaccinated. Study 
participants were reimbursed ZAR20 (~USD2) at each visit for 
travel costs.
HCV screening was performed with the Roche Cobas 6000 analy ser: 
Module e601 (Roche, Switzerland). Because of funding constraints, 
liver function tests, HIV testing and HCV viral load and genotype 
testing were not included in the study; however, HIV, HCV and 
genotype results could be obtained for some participants. 
Basic descriptive statistics were used to summarise cohort 
character istics using Stata version 12.0 (StataCorp., USA). 
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Ethical approval
The study received ethical approval from the Human Sciences 
Research Ethics Committee, University of Cape Town (ref. no. 
HSREC 494/2014). Study activities complied with the Declaration 
of Helsinki. 
Results
Forty-two MSM were enrolled. One was withdrawn from analysis 
owing to missing data. Baseline characteristics are summarised in 
Table 2. The median age was 26 (IQR 30 - 40) years. Ethnically, 
most were mixed race (n=23; 56%) or white (n=16; 39%); 39 (95%) 
participants identified as male, and 2 (5%) as transgender women. 
Participants’ self-reported sexual orientation was homosexual (n=18; 
44%), bisexual (n=16; 39%), and heterosexual (n=5; 12%), while 2 
(5%) did not disclose their sexual orientation. 
The median duration of drug use was 11 (IQR 9 - 15) years. Drugs 
used included heroin and crystal methamphetamine, with 33 (80%) 
and 37 (90%), respectively, reporting use in the past 3 months; 28 
(68%) stated that heroin was their drug of choice and 27 (67%) 
that crystal methamphetamine was their main drug. Thirty-three 
(80%) reported injecting drugs in the past 3 months, while 36 (88%) 
reported having ever injected drugs. Twenty-two (54%) disposed of 
used needles in regular garbage bins, 2 (5%) indicated that they kept 
needles for re-use, and 11 (27%) reported returning needles to the 
harm-reduction programme site, while 29 (71%) admitted having 
ever shared used needles, syringes or drug preparation equipment. 
The median number of sexual partners reported in past 3 months 
was 2 (IQR 1 - 6), 11 (27%) reported not using a condom in the past 
3 months, and only 6 (15%) reported consistent condom use. 
Eleven of the 41 (27%) participants screened positive for anti-HCV 
IgG. 
HIV serological results were available for 30 (73%) of the enrolled 
participants; of these, 12/30 (40%) were HIV-seropositive. HIV status 
was known in 8/11 participants with positive HCV IgG results, and 
3/8 (37.5%) were HIV-positive. 
Nucleic acid test results were subsequently available for 6 patients 
with positive HCV IgG, while 1 was PCR-negative (infection pre-
sumed cleared). For the other 5 participants, genotypes included: 
3 genotype 1b, 1 genotype 1a, and 1 genotype 4b.
Ten of 11 anti-HCV seropositive cases (91%) were also positive for 
HBV surface antigen, implying either exposure to HBV or anti-HBV 
vaccination.
One participant screened positive for HBV infection (positive 
HBV surface antigen), but none screened positive for both HCV and 
HBV. These results are summarised in Fig. 1. 
Discussion
To our knowledge, this is the first description of HCV prevalence 
and risk factors among SA MSM who use drugs. The observed 
seroprevalence of 27%, compared with reports from sub-Saharan 
Africa, is high. Comparable rates in PWID populations include 
16.4% in Malindi, Kenya, 22.2% in Nairobi, Kenya, 7.7% in Lagos, 
Nigeria, 23.3% in Dakar, Senegal and 27.7% in Temeke, Dar-es-
Salaam, Tanzania.[23-27] The observed seroprevalence is lower than 
the reported range of 22 - 94% in the Maghreb region of north 
Africa.[28]
These results imply a considerable HCV disease burden in SA 
among drug-using MSM. Given that screening in the general 
Table 1. Reported HCV seroprevalence in South Africa
Study reference Study period Province/region Population n Serology rates, %
Gededzha et al.[17] 2004 - 2006 Gauteng HIV-positive 653 1.2
Gogela et al.[18] Not stated Western Cape HIV-positive 313 3.2
Firnhaber et al.[19] Not stated Gauteng HIV-positive 502 0.0
Hoffmann et al.[20] 2002 Gauteng HIV-positive, 
antenatal clinic 
994 0.1
Barth et al.[21] Sept. - Nov. 2008 Limpopo HIV-positive, clinic 258 0.8
Amin et al.[12] 1995 - 1996, 
52 weeks follow-up
Multisite in SA HIV-positive,
SA participants were 
mainly white
- 1.9
Lodenyo et al.[22] 1999 Gauteng HIV-positive 100 1.0
Parboosing et al.[15] Jan. 2004 - June 2005 KwaZulu-Natal HTC specimens 1 937 6.4
Only HIV-positive 
specimens
- 13.4
Only HIV-negative 
specimens
- 1.7
Tathiah et al.[14] 2002 - 2010 KwaZulu-Natal Routine tests submitted 
to tertiary laboratory  
(with differing 
denominators)
- -
All anti-HCV Ig tests 79 216 4.1
Of those tested for HIV: 
HIV-positive
3 425 5.1
Of those tested for HIV: 
HIV-negative
14 696 1.8
HCV = hepatitis C virus; Sept. = September; Nov. = November; Jan. = January; SA = South Africa; HTC = routine HIV testing and counselling specimens.
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population and HIV-positive populations yields a seroprevalence 
rate of 0.3 - 1.0%, our results would justify focusing HCV screening 
and services on key and vulnerable populations of MSM and PWID. 
Clinical awareness of HCV among specific populations of PLWA, 
including PWID, MSM, transgender individuals, sex workers and 
prisoners, must be promoted.[3] The association between HIV and 
HCV infection, which includes sexual transmission of HCV, should 
be considered.[12] It is well described that individuals from key 
populations experience real or perceived stigma from both society at 
large and the healthcare sector, which results in lower levels of health 
access and adverse health outcomes. HCV appears to be concentrated 
among key populations in SA, which provides a further obstacle to 
addressing the burden of HCV disease. There is an ethical imperative 
to work towards creating an enabling and non-discriminatory 
healthcare environment, where individuals from key populations 
are welcomed and where their specific health concerns, such as 
HCV screening, can be accommodated. Clinicians may require 
sensitivity training to enable them to engage with key population risk 
groups regarding HCV exposure and infection. Referral pathways for 
specialist management (and cure) of people with HCV infection or 
complications, such as liver fibrosis or cirrhosis, are necessary.
PWID need access to syringe and needle exchange and opiate 
drug-substitution therapy,[3] delivered in enabling and de-stigmatised 
environments as per the recommendations of the WHO for 
prevention of HIV and HCV.[5,29]
Currently, it appears as if the HCV epidemic is concentrated in 
specific populations rather than being a generalised epidemic. This 
knowledge should assist health planners with regard to current and 
future responses to HCV. Further research is necessary, including 
better mapping of at-risk populations, as well as population level 
surveillance.[3]
HCV is treatable with new oral DAA drugs, which dramatically 
improve cure rates and side-effect profiles.[2,3] These drugs should 
Table 2. Summary of characteristics of enrolled participants 
(N=41)
Variable, participant 
demographics n (%) Median (IQR)
Age at enrolment, years - 26 (30 - 40)
Race
Mixed 23 (56) -
White 16 (39) -
Black African 1 (2) -
Asian 1 (2) -
Sexual orientation
Bisexual 16 (39) -
Gay 18 (44) -
Straight 5 (12) -
Reported drug use
Duration, years - 11 (9 - 15)
Drugs used in the past 3 months 
Heroin 33 (80) -
Crystal methamphetamine 37 (90) -
Other 19 (46) -
Main (preferred) drugs used 
Heroin 28 (68) -
Crystal methamphetamine 27 (66) -
Other 12 (32) -
Place of use
Home 22 (54) -
Friend’s home 16 (39) -
Party 8 (20) -
Street 21 (51) -
Bar/club/shebeen 7 (17) -
Sex party 6 (15) -
 Other (graveyard, work, public 
toilet, vehicle, unspecified)
8 (20) -
Drug-injecting behaviour
Ever injected 36 (88) -
In the past 3 months    33 (80) -
Non-intravenous 32 (78) -
Intravenous and non-intravenous 27 (66) -
 Ever shared equipment or needles 29 (71) -
Needle and drug-equipment 
disposal
Rubbish bin 22 (54) -
Kept for re-use 2 (5) -
Returned to clinic 11 (27) -
Not available 6 (14) -
Sexual behaviour
 Sexual partners in the past 3 
months, n
- 2 (1 - 6)
Condom use in the past 3 months
Never 11 (27) -
Some of the time 6 (15) -
Most of time 13 (32) -
All of the time 6 (15) -
Not reported/applicable 5 (12) -
IQR = interquartile range.
Fig. 1. Viral serostatus: number and percentage of a total of 41 participants. 
(HCV = hepatitis C virus; HBV surface Ag = hepatitis B virus surface antigen.)
HIV-positive
HCV IgG+ HBV surface Ag+
8 (20%)
3 (7%)
8 (20%)
1 (2%)
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allow for easier expansion of treatment access.[3] DAA therapy 
needs to be made available, accessible and affordable. Policymakers, 
government and civil groups should advocate for the treatment of 
HCV. The need to treat HIV and HCV co-infected people has to be 
emphasised.[3] 
Study limitations
The small sample size and convenience sampling method conducted 
at one specialist clinic site limit generalisability of our results. 
Financial constraints precluded RT-PCR to confirm active HCV 
infection or genotyping for all participants. 
Accuracy of responses to study questions depends on respondents’ 
memory and recall. Additionally, experiences of stigma and 
discrimination in the health environment with regard to MSM’s 
sexual behaviours and drug use might have made responses subject 
to social desirability bias. The extensive experience of ITCMH and 
Anova Health Institute’s Health4Men initiative in working together 
with MSM and PWID regarding their psychological and physical 
health should mitigate this bias to some extent. 
Recommendations
Valid diagnostic algorithms for HCV need to be developed, with 
specific consideration of the disease epidemiology in African 
populations.[3,9] Standardisation of testing algorithms will allow 
realistic comparison across studies. Evidence-based normative 
guidance would also allow clinicians an efficient investigatory path 
for diagnosing HCV infection and promote linkage to care. 
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